Condition: Transformed Splenic Marginal Zone Lymphoma · Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
This description comes directly from the study's public registry record.
IELSG Study Coordination Office · +41 58 666 7321 · ielsg@ior.usi.ch
Davide Rossi, MD · +41 91 811 8540 · davide.rossi@eoc.ch
Always discuss trial participation with your own doctor first.
| Columbia University | New York, New York, United States | Not Yet Recruiting |
| Universitz Hospitals Leuven | Leuven, Belgium | Not Yet Recruiting |
| Hôpital Saint Louis | Paris, France | Recruiting |
| Fondazione IRCCS Policlinico San Matteo | Pavia, Italy | Recruiting |
| Hospital Clínic de Barcelona | Barcelona, Spain | Recruiting |
| Oncology Institute of Southern Switzerland | Bellinzona, Switzerland | Not Yet Recruiting |
| University Hospitals Dorset | Bournemouth, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06712459